z-logo
open-access-imgOpen Access
Sex differences in COPD-related quadriceps muscle dysfunction and fibre abnormalities
Author(s) -
Sharanya Adithya,
Ciano Margherita,
Withana Shirmila,
Kemp Paul Richard,
Polkey Michael Iain,
Sathyapala Samantha Amanda
Publication year - 2019
Publication title -
chronic respiratory disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.929
H-Index - 41
eISSN - 1479-9731
pISSN - 1479-9723
DOI - 10.1177/1479973119843650
Subject(s) - medicine , copd , weakness , wasting , muscle weakness , atrophy , muscle atrophy , cohort , cardiology , physical therapy , surgery
In chronic obstructive pulmonary disease (COPD), lower limb dysfunction is associated with reduced exercise capacity, increased hospitalizations and mortality. We investigated sex differences in the prevalence of quadriceps dysfunction and fibre abnormalities in a large COPD cohort, controlling for the normal sex differences in health. We compared existing data from 76 male and 38 female COPD patients where each variable was expressed as a function of gender-specific normal values (obtained from 16 male and 14 female controls). Female COPD patients had lower quadriceps muscle strength and peak workload on a maximal incremental cycle ergometry protocol compared to male patients. Female patients had a smaller type II fibre cross-sectional area (CSA) compared to male patients, suggesting a greater female preponderance to fibre atrophy, although this result was largely driven by a few male patients with a large type II fibre CSA. Female patients had significantly higher concentrations of a number of plasma pro-inflammatory cytokines including tumour necrosis factor alpha and interleukin 8 (IL8), but not lower levels of physical activity or arterial oxygenation, compared to males. Our data confirm results from a previous small study and suggest that female COPD patients have a greater prevalence of muscle wasting and weakness. Larger studies investigating sex differences in COPD-related muscle atrophy and weakness are needed, as the results will have implications for monitoring in clinical practice and for design of clinical trials evaluating novel muscle anabolic agents.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom